Novel Platinum-Based Drug Targeting Tumor Microenvironment （HJ-550 ）

significantly outperforming current first-line chemotherapy drugs (such as traditional platinum drugs, paclitaxel, and adriamycin) in treating highly lethal cancers like lung cancer, gastric cancer, and triple-negative breast cancer.